What is the safest first‑line selective serotonin reuptake inhibitor (SSRI) for an older adult (≥ 65 years) with major depressive disorder and no contraindicating comorbidities?

Best SSRI for Geriatric Depression

For older adults (≥65 years) with major depressive disorder, sertraline and citalopram are the preferred first-line SSRIs, with escitalopram as an equally appropriate alternative. These agents offer the most favorable balance of efficacy, tolerability, and safety in the geriatric population.

Preferred First-Line SSRIs

The American Family Physician guidelines explicitly recommend the following agents for older patients with depression 1:

• Sertraline (Zoloft): 25-50 mg daily initially, up to 200 mg daily
• Citalopram (Celexa): 10 mg daily initially, up to 40 mg daily
• Escitalopram (Lexapro): 10 mg daily initially, up to 20 mg daily

Why These Three Stand Out

Sertraline has the most comprehensive evidence base in geriatric populations 2. It demonstrates:

• Equivalent efficacy to tricyclic antidepressants but with superior tolerability 2
• Significantly better quality of life outcomes compared to nortriptyline 2
• The lowest potential for cytochrome P450-mediated drug interactions among SSRIs, which is critical given polypharmacy in older adults 2
• Well-tolerated adverse effect profile similar to younger patients 2

Citalopram and escitalopram are recommended because they are well-tolerated and have fewer drug-drug interactions compared to other SSRIs 1, 3, 4.

SSRIs to Avoid in Older Adults

Paroxetine and fluoxetine should generally be avoided in geriatric patients 1:

• Paroxetine: Higher anticholinergic burden, increasing risk of confusion, falls, and cognitive impairment 1
• Fluoxetine: Very long half-life (can exceed 1 week with active metabolites), causing prolonged side effects and delayed resolution of adverse drug interactions; greater risk of agitation and overstimulation 1, 4

Dosing Strategy: "Start Low, Go Slow"

Begin with approximately 50% of the standard adult starting dose 1:

• Older adults have altered pharmacokinetics and pharmacodynamics 5
• They are at significantly greater risk for adverse drug reactions 1
• Titrate gradually based on response and tolerability 1

Treatment Duration

Continue antidepressant therapy for at least 4-12 months after achieving remission for a first episode 1. For recurrent depression:

• After 2 episodes: Consider 1-3 years of maintenance therapy 3
• After 3+ episodes: Consider indefinite maintenance therapy 1, 3

Common Pitfalls to Avoid

1. Drug-drug interactions: Older adults average 5+ medications. Fluoxetine, fluvoxamine, and paroxetine have the highest interaction potential through cytochrome P450 inhibition 4, 2. Sertraline and citalopram have the lowest 4, 2.

2. Anticholinergic burden: Avoid paroxetine in patients with cognitive impairment, urinary retention, constipation, or fall risk 1.

3. Premature discontinuation: Approximately 63% of patients experience at least one adverse effect, with nausea being most common 1. These often resolve within 2-3 weeks; counsel patients to continue therapy 1.

4. Hyponatremia: SSRIs can cause SIADH, particularly in older adults. Monitor sodium levels, especially in the first few weeks 5.

Alternative Considerations

If SSRIs are contraindicated or ineffective, mirtazapine, venlafaxine, and bupropion are appropriate alternatives 1. However, note that:

• Venlafaxine (SNRI) has slightly higher discontinuation rates due to nausea and vomiting compared to SSRIs 1
• Mirtazapine causes sedation and weight gain, which can be beneficial for patients with insomnia and poor appetite 1

Efficacy Expectations

All SSRIs show modest superiority over placebo with a number needed to treat of 7-8 for achieving remission 1. Antidepressants are most effective in patients with severe depression rather than mild-to-moderate symptoms 1.